Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT01531673
First received: February 1, 2012
Last updated: May 5, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 5, 2015